Loading
A phase 2 trial of Dexamethasone in multiple myeloma, run by C4 Therapeutics, Inc., now recruiting.
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07284758 by C4 Therapeutics, Inc., with 100 participants planned, started 2026-02-18 and due to reach its primary completion in 2030-03. Interventions recorded: Cemsidomide, Dexamethasone. Conditions listed: Multiple Myeloma, Relapsed/Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/